By taking different approaches to functionally impair EZH2 activity we report here that use of a substrate-competitive dual EZH2-G9A/GLP inhibitor, but not SAM-competitive EZH2 inhibitors can promote differentiation of human AML cells. This evidence concerns the gene EHMT1 and acute myeloid leukemia.